Clinical trials
Diffuse Midline Glioma clinical trials
Below are recruiting diffuse midline glioma clinical trials, each written for real people, not researchers. We’re tracking 31 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05259605Recruiting
Study uses brain tumor tissue and scans to track treatment outcomes
This is an observational study that collects and compares information from patients with primary brain tumors and their treatment results. It uses stored tumor tissue and brain scans to better understand outcomes using updated tumor classification methods.
InnsbruckAges 18 years+ - NCT07796061RecruitingPhase 1
Ultrasound plus immune cells for brain tumors
This trial tests a new way to treat a type of brain tumor called diffuse midline glioma. It uses focused ultrasound to open a tiny gap in the blood-brain barrier, which may help special immune cells (T-cells) reach and attack the tumor. The goal is to see if this combination is safe and helpful.
Washington D.C., District of ColumbiaAges 3–25 - NCT06357377RecruitingPhase 1
NEO100 for children with high-grade brain tumors
This trial tests a new drug called NEO100 for children with certain types of brain tumors. It is given through a needle into the tumor or nearby fluid, and the study looks at safety and the right dose.
Orange, CaliforniaAges 5–18 - NCT05544526RecruitingPhase 1
CAR T cell treatment for brainstem spinal cord tumor in children
This Phase 1 trial tests CAR T cells designed to attack a specific target (GD2) on a rare childhood brain/spinal tumor called DMG with a certain gene change (H3K27M). It is mainly designed to check safety and early signs of effectiveness after prior treatments.
LondonAges Up to 16 years - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT04655404RecruitingEarly Phase 1
Larotrectinib for children with newly diagnosed glioma with NTRK fusion
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
Aurora, ColoradoAges Up to 21 years - NCT06720727Recruiting
Radiation therapy for children with histone-altered midline glioma
This trial tests a type of radiation therapy called craniospinal irradiation for children and teenagers newly diagnosed with a specific brain tumor (diffuse midline glioma with H3 histone alteration). The goal is to see if this radiation can help control the tumor.
MumbaiAges 3–18
Hear when a new Diffuse Midline Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diffuse midline glioma?
- Yes. Clin2 currently lists 31 recruiting diffuse midline glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse midline glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse midline glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.